Psyence Biomedical (PBM) Stock Price, News & Analysis

Company Overview

Psyence Biomedical, Inc. is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for unmet mental health needs. The company’s research centers on psilocybin, a naturally occurring psychedelic compound, and its potential use in combination with psychological support.

Psyence Biomedical’s lead development program is aimed at treating adjustment disorder in patients receiving palliative care. The company is investigating a psilocybin-based drug product designed to address emotional and psychological distress associated with serious illness, while seeking to establish a standardized treatment approach suitable for clinical and medical settings.

The company was formed through a business combination involving Newcourt Acquisition Corp. and became publicly traded on the Nasdaq under the symbol PBM in 2024. Its development activities have included work with clinical and research partners in international markets, including Australia. Psyence Biomedical is part of the broader Psyence platform, which has focused on the research and development of nature-derived psychedelic therapeutics.

Key Stats

• Today's Range: $4.16 to $4.53
• 50-Day Range: $3.35 to $6.63
• 52-Week Range: $1.92 to $22.25
• Volume: 26,499 shs
• Average Volume: 79,214 shs
• Market Capitalization: $9.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Psyence Biomedical Stock Analysis - MarketRank™

Psyence Biomedical scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Psyence Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Psyence Biomedical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Psyence Biomedical is 0.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Psyence Biomedical is 0.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

Psyence Biomedical has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.21% of the float of Psyence Biomedical has been sold short.

Short Interest Ratio / Days to Cover

Psyence Biomedical has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Psyence Biomedical has recently decreased by 44.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Psyence Biomedical does not currently pay a dividend.

Dividend Growth

Psyence Biomedical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Psyence Biomedical has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

Only 2 people have searched for PBM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Psyence Biomedical insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of Psyence Biomedical is held by insiders.

Percentage Held by Institutions

77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 1/23/2025
• Today: 10/16/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PBM
• Previous Symbol: NASDAQ:PBM
• CIK: 1985062
• Web: www.psyence.com
• Phone: 510-214-3750
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.62
• Quick Ratio: 14.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.39 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 2,290,000
• Free Float: 2,210,000
• Market Cap: $9.66 million
• Optionable: N/A
• Beta: 1.68